Immunic Inc. | VTL - Net Income

Vital Therapies reported $-56474000 in Net Income for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Net Income Change
Biomarin Pharmaceutical BMRN:US USD -249000 6.4M
Dynavax Technologies DVAX:US USD 67.73M 3.92M
Enanta Pharmaceuticals ENTA:US USD -28986000 2.64M
Insmed INSM:US USD -160123000 28.98M
Intercept Pharmaceuticals ICPT:US USD -20825000 288.28M
Mirati Therapeutics MRTX:US USD -202475000 28.91M
Omeros OMER:US USD 128.73M 146.19M
Orasure Technologies OSUR:US USD 15.56M 10.29M
Quidel QDEL:US USD 30.3M 11.1M
Regulus Therapeutics RGLS:US USD -7551000 293K
Revance Therapeutics RVNC:US USD -145952000 61.26M
Ultragenyx Pharmaceutical RARE:US USD -151833000 93.27M
United Therapeutics UTHR:US USD 132.1M 107.2M
Vital Therapies VTL:US USD -56474000 35.25M
Xoma XOMA:US USD -5976000 1.8M